JP2020520936A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020520936A5 JP2020520936A5 JP2019563863A JP2019563863A JP2020520936A5 JP 2020520936 A5 JP2020520936 A5 JP 2020520936A5 JP 2019563863 A JP2019563863 A JP 2019563863A JP 2019563863 A JP2019563863 A JP 2019563863A JP 2020520936 A5 JP2020520936 A5 JP 2020520936A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- formula
- disorders
- disorder
- formula iib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 18
- 206010012289 Dementia Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 7
- 208000020016 psychiatric disease Diseases 0.000 claims 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
- 208000016285 Movement disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000007472 neurodevelopment Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 1
- 208000015891 sexual disease Diseases 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- LJNFYMMXCXGFCP-UHFFFAOYSA-N COC1(CNCC1)c1cccc(F)c1F Chemical compound COC1(CNCC1)c1cccc(F)c1F LJNFYMMXCXGFCP-UHFFFAOYSA-N 0.000 description 1
- LJNFYMMXCXGFCP-LLVKDONJSA-N CO[C@]1(CNCC1)c1cccc(F)c1F Chemical compound CO[C@]1(CNCC1)c1cccc(F)c1F LJNFYMMXCXGFCP-LLVKDONJSA-N 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17171938.8 | 2017-05-19 | ||
| EP17171938 | 2017-05-19 | ||
| EP17195451.4 | 2017-10-09 | ||
| EP17195451 | 2017-10-09 | ||
| EP17207406.4 | 2017-12-14 | ||
| EP17207406 | 2017-12-14 | ||
| EP18151428 | 2018-01-12 | ||
| EP18151428.2 | 2018-01-12 | ||
| PCT/EP2018/063123 WO2018211080A1 (en) | 2017-05-19 | 2018-05-18 | (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020520936A JP2020520936A (ja) | 2020-07-16 |
| JP2020520936A5 true JP2020520936A5 (enExample) | 2021-04-08 |
| JP7126522B2 JP7126522B2 (ja) | 2022-08-26 |
Family
ID=62599537
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019563863A Active JP7126522B2 (ja) | 2017-05-19 | 2018-05-18 | （＋）－３－（２，３－ジフルオロフェニル）－３－メトキシピロリジンまたはその薬学的に許容される塩、それを調製するための方法およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11078158B2 (enExample) |
| EP (1) | EP3625213B1 (enExample) |
| JP (1) | JP7126522B2 (enExample) |
| CN (1) | CN110621659B (enExample) |
| DK (1) | DK3625213T3 (enExample) |
| ES (1) | ES2943252T3 (enExample) |
| FI (1) | FI3625213T3 (enExample) |
| PL (1) | PL3625213T3 (enExample) |
| WO (1) | WO2018211080A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12275694B2 (en) * | 2019-05-24 | 2025-04-15 | Irl 790 Ab | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof |
| CA3180417A1 (en) * | 2020-06-10 | 2021-12-16 | Guillaume Dutheuil | Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid |
| CN117430540A (zh) * | 2022-07-14 | 2024-01-23 | 上海艾力斯医药科技股份有限公司 | 一种吡咯烷化合物及其制备方法 |
| WO2025003437A1 (en) | 2023-06-28 | 2025-01-02 | Integrative Research Laboratories Sweden Ab | A pharmaceutical composition comprising a fumaric acid salt of (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0586229A1 (en) * | 1992-09-01 | 1994-03-09 | Zeneca Limited | 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors |
| EP1582524B1 (en) | 2004-04-02 | 2008-08-13 | Ludwig Maximilians Universität | Method of preparing organomagnesium compounds |
| AU2008258599B2 (en) * | 2007-06-05 | 2013-06-13 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpyrrolidines as modulators of cortical catecholaminergic neurotransmission |
| WO2010058019A1 (en) * | 2008-11-24 | 2010-05-27 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| CN106957252B (zh) * | 2014-11-19 | 2019-11-19 | 连云港恒运药业有限公司 | 一种质子泵抑制剂中间体及其制备方法 |
-
2018
- 2018-05-18 EP EP18730980.2A patent/EP3625213B1/en active Active
- 2018-05-18 FI FIEP18730980.2T patent/FI3625213T3/fi active
- 2018-05-18 JP JP2019563863A patent/JP7126522B2/ja active Active
- 2018-05-18 CN CN201880031878.8A patent/CN110621659B/zh active Active
- 2018-05-18 WO PCT/EP2018/063123 patent/WO2018211080A1/en not_active Ceased
- 2018-05-18 PL PL18730980.2T patent/PL3625213T3/pl unknown
- 2018-05-18 ES ES18730980T patent/ES2943252T3/es active Active
- 2018-05-18 DK DK18730980.2T patent/DK3625213T3/da active
- 2018-05-18 US US16/338,055 patent/US11078158B2/en active Active
-
2021
- 2021-06-25 US US17/358,494 patent/US12091384B2/en active Active
-
2024
- 2024-08-13 US US18/802,081 patent/US20240400505A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6043935B2 (ja) | ピペラジノトリアゾール化合物及びその製造方法と製薬用途 | |
| EP2951158B1 (en) | Process for the preparation of ivacaftor and solvates thereof | |
| JP2011513485A5 (enExample) | ||
| TW201002682A (en) | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine | |
| JP2005538187A (ja) | 新規キヌクリジン誘導体及びその使用方法 | |
| CN1659170A (zh) | 噻吩基化合物 | |
| CN105473568B (zh) | 1,7‑萘啶衍生物 | |
| CA3057923A1 (en) | A crystalline form of (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride monohydrate | |
| IL288271B2 (en) | Pharmaceutically acceptable salts of [2-(3-fluoro-5-methanesulfonylphenoxy)ethyl](propyl)amine and their uses | |
| JP7116060B2 (ja) | Ｒ－６－ヒドロキシ－８－［１－ヒドロキシ－２－［２－（４－メトキシフェニル）－１，１－ジメチルエチルアミノエチル］－２ｈ－１，４－ベンゾオキサジン－３（４ｈ）－オン塩酸塩の改良された製造法 | |
| FI3625213T3 (fi) | (+)-3-(2,3-Difluorifenyyli)-3-metoksipyrrolidiini-fumaraatti, menetelmä sen valmistamiseksi ja sen käytöt | |
| CN111518020A (zh) | Magl抑制剂及其制备方法、用途 | |
| CN1451006A (zh) | 1－[烷基]、1－[(杂芳基)烷基]和1－[(芳基)烷基]－7－吡啶基－咪唑并[1,2－a]嘧啶－5(1H)－酮衍生物 | |
| MX2007009816A (es) | Sales de tartrato y de malato de trans-1-((1r,3s)-6-cloro-3- fenilindan-1-i1)-3,3-dimetilpiperazina. | |
| CN101119983B (zh) | 反式-1-((1r,3s)-6-氯-3-苯基茚满-1-基)-3,3-二甲基哌嗪的结晶碱 | |
| UA79248C2 (en) | Mandelate salts of substituted tetracyclic tetrahydrofuran derivatives | |
| TW201102370A (en) | Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine | |
| WO2010122774A1 (ja) | (１ｓ,６ｓ)または(１ｒ,６ｒ)-シス-２,８-ジアザビシクロ[４.３.０]ノナンおよびその中間体の製造法 | |
| CN107602518B (zh) | 香豆素-二硫代氨基甲酸酯衍生物及其合成方法 | |
| CN103664781B (zh) | 盐酸屈他维林晶型i和晶型ii及制备方法 | |
| JP2003523991A (ja) | （２ｓ）−アミノインダン誘導体、その製法および選択的ドーパミンｄ３リガンドとしてのその使用 | |
| CN107556308B (zh) | 1-芳基-1H-吡啶[3,4-b]吲哚-3-羧酸甲酯衍生物的不对称合成 | |
| JP2020172512A (ja) | Ｍｇｌｕ５受容体のネガティブアロステリック調節因子の多型 | |
| CN1914200A (zh) | 烟碱性乙酰胆碱受体配件 | |
| CN120092001A (zh) | 用于制造alogabat的方法 |